Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 1.00 |
| ▸ | EED | O75530 | 1/20 | 0.69 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.69 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.69 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.69 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13282036 | 0.92 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL15710401 | 0.89 | EZH2 (0.94) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL15710299 | 0.89 | EZH2 (0.94) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13467767 | 0.87 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL17804384 | 0.86 | EZH2 (0.89) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13467972 | 0.86 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13276561 | 0.86 | EZH2 (0.86) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL15709908 | 0.85 | EZH2 (0.88) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL15709910 | 0.85 | EZH2 (0.88) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13281165 | 0.85 | EZH2 (0.87) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3536314-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3470396-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3470396-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2825161-B1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-3165520-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme Inc (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-3165520-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme Inc (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20170065600-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-03-09 | — | — | US | disclosed |
| US-20170065600-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-03-09 | — | — | US | disclosed |
| US-20160332969-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2016-11-17 | — | — | US | disclosed |
| US-9376422-B2 | Dihidropyridin-2-one benzamine compounds | Epizyme, Inc. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9175331-B2 | Inhibitors of human EZH2, and methods of use thereof | Epizyme, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140275081-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275081-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2013138361-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130040906-A1 | Inhibitors of Human EZH2, and Methods of Use Thereof | Epizyme, Inc. | 2013-02-14 | — | — | US | disclosed |
| US-20130040906-A1 | Inhibitors of Human EZH2, and Methods of Use Thereof | Epizyme, Inc. | 2013-02-14 | — | — | US | disclosed |
| WO-2012142513-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275081-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | EZH2, DOT1L, PRDM7 | EZH2 1/4885EED 12/4885RBBP4 178/4885 |
| US-20170065600-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | EZH2, DOT1L, PRDM7 | EZH2 1/4885EED 12/4885RBBP4 178/4885 |
| US-20140142083-A1 | Substituted Benzene Compounds | CYP1B1, TP53, VHL | EZH2 2519/4885EED 1592/4885RBBP4 253/4885 |
| US-20130040906-A1 | Inhibitors of Human EZH2, and Methods of Use Thereof | EZH2, DOT1L, PRDM7 | EZH2 1/4885EED 12/4885RBBP4 178/4885 |
| US-20160332969-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | EZH2 2519/4885EED 1592/4885RBBP4 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.